GRFS News and Press, Grifols S.A. From 04/23/25

2025-04-23 11:10:00 ET Summary Grifols, a Spanish multinational specializing in plasma-derived therapies, is undervalued due to historical mismanagement but holds a strong market position with significant competitive advantages. New management has implemented an operational improv...

2025-04-23 10:50:00 ET Summary The White Falcon portfolio underperformed due to losses in larger positions, despite gains from gold and silver royalties; Converge Technologies was acquired at a premium. Market volatility increased post-quarter due to President Trump's tariff annou...

2025-04-02 05:44:43 ET Stock futures dipped on Wednesday as investors braced for President Trump's impending tariff announcement amidst lingering market unease.... Read the full article on Seeking Alpha For further details see: Biggest stock movers Wednesday: NCNO, TTEC, GRF...

2025-04-02 04:01:17 ET Canadian investment fund Brookfield ( NYSE: BAM ) resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols ( NASDAQ: GRFS ), El Confidencial reported on Wednesday, citing industry sources. This development comes four months ...

2025-03-10 12:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Air France-KLM ADR (AFLYY) is expected to report $0.02 for Q4 2024 Viracta Therapeutics Inc. (VIRX) is expected to report for Q4 2024 BJ's Wholesale Club Holdings Inc. (BJ) is expected to report $0.89 for Q4 2025 Deutsche Lufthansa AG ADR - Level I (DLAKY) is expected to report $0.22 ...

2025-02-27 12:58:12 ET Summary Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ra...

2025-02-06 13:46:07 ET Summary ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's high-titer plasma offers superior protection with mi...

2025-01-23 10:03:24 ET More on Grifols S.A. Grifols, S.A. 2024 Q3 - Results - Earnings Call Presentation Grifols: More Attractive Than In A Very Long Time Grifols, S.A. (GRFS) Q3 2024 Earnings Call Transcript Key deals this week: EnLink Midstream, Peabody, St...

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapies Part of broad Grifols program to find disea...